Stage I/Smoldering Myeloma Multiple Myeloma

Denosumab More Effective Than Zometa at Delaying Bone Complications (10-15-2010)

Among patients with multiple myeloma or bone metastases from breast cancer, prostate cancer, or other solid tumors, denosumab was more effective than Zometa® (zoledronic acid) at delaying or preventing bone complications such as fracture. Results from... Continue Reading

Benefit of Velcade on Myeloma Survival Added to Prescribing Information (03-5-2010)

The U.S. Food and Drug Administration (FDA) has approved expanded prescribing information for Velcade® (bortezomib). Velcade’s label now includes results from the VISTA study, which show that Velcade improves long-term overall survival among patients... Continue Reading

Velcade® Improves Response Rate After High-dose Melphalan for Myeloma (12-21-2009)

Among patients who have received high-dose melphalan and an autologous stem cell transplant for initial treatment of multiple myeloma, Velcade® (bortezomib) appears to improve treatment response rates. These results were presented at the 2009 meeting... Continue Reading

Revlimid® Delays Progression of Multiple Myeloma (12-18-2009)

Among multiple myeloma patients who have had an autologous stem cell transplant, additional treatment with Revlimid® (lenalidomide) delays cancer progression. These results were released by the National Cancer Institute. Multiple myeloma is a cancer... Continue Reading

Pesticides Linked to Precancerous Blood Disorder (06-24-2009)

Pesticides Linked to Precancerous Blood Disorder Individuals who apply pesticides to crops are twice as likely as the general population to develop a precancerous blood disorder called MGUS (monoclonal gammopathy of undetermined significance), which can... Continue Reading

Formaldehyde Exposure May Increase Risk of Blood and Lymphatic Cancers (06-23-2009)

Formaldehyde Exposure May Increase Risk of Blood and Lymphatic Cancers Industrial workers who are exposed to formaldehyde may be at an increased risk of dying from blood and lymphatic cancers, particularly myeloid leukemia but also Hodgkin’s lymphoma... Continue Reading

Additional Evidence Shows Thalomid® Improves Survival in Elderly with Multiple Myeloma (03-8-2009)

Additional Evidence Shows Thalomid® Improves Survival in Elderly with Multiple Myeloma According to results recently presented at the 2007 annual meeting of the American Society of Hematology, additional evidence confirms that the addition of Thalomid®... Continue Reading

Velcade® Approved for Initial Therapy of Multiple Myeloma (03-8-2009)

Velcade® Approved for Initial Therapy of Multiple Myeloma The United States Food and Drug Administration (FDA) has approved Velcade® (bortezomib) as initial therapy for the treatment of multiple myeloma. Velcade is already approved for the treatment... Continue Reading

Velcade® Combinations for Newly Diagnosed Patients with Multiple Myeloma at ASH 2008 (03-8-2009)

Velcade® Combinations for Newly Diagnosed Patients with Multiple Myeloma at ASH 2008 At the 2008 meeting of the American Society of Hematology (ASH) in December in San Francisco, there were several oral presentations on the outcomes of newly diagnosed... Continue Reading

Revlimid® Combinations for Newly Diagnosed Multiple Myeloma Reported at ASH 2008 (03-8-2009)

Revlimid® Combinations for Newly Diagnosed Multiple Myeloma Reported at ASH 2008 At the 2008 meeting of the American Society of Hematology (ASH) in December, there were several oral presentations on the outcomes of newly diagnosed patients with multiple... Continue Reading

« Previous PageNext Page »